title: [Alzheimer's disease: New therapeutic strategies].
abstract: The rapid increase in prevalence rates of Alzheimer's disease means that treatments to prevent, stop or reverse this devastating disease are urgently needed. Despite advances in understanding its molecular pathology, there are no drugs that can halt its progression. This review takes a tour through phase 2, or higher studies, probing receptor agonist agents interfering with aggregation, inhibitors/modulators of secretases, lipid-lowering agents, and, finally and most extensively, immunotherapy. The fact that phase 3 studies with bapineuzumab and solaneuzumab have recently failed does not invalidate the potential of immunotherapy, as more information is available and new clinical trials are being initiated.
authors.affiliation: Protein Folding and Stability Group, Unitat de Biociències, Departament de Bioquímica i Biología Molecular, Universitat Autònoma de Barcelona, Cerdanyola del Vallés, España. Electronic address: sandra.villegas@uab.cat.
authors.forename: Sandra
authors.initials: S
authors.lastname: Villegas
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000209:etiology; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use*; D011134:Polysaccharides / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D018680:Cholinergic Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D007155:Immunologic Factors; D018697:Nootropic Agents; D011134:Polysaccharides; C486237:alzhemed; D053829:Amyloid Precursor Protein Secretases
keywords: Alzheimer's disease; Amyloid-β; Enfermedad de Alzheimer; Immunotherapy; Inmunoterapia; New therapies; Nuevos tratamientos; Vaccine; Vacuna; β-amiloide